Clinical development of a new inactivated hepatitis A vaccine

Infection

Volumn 24, Issue 6, 1996, Pages 447-458

  Vidor, E ^a   Fritzell, B ^a   Plotkin, S ^a  

^a Pasteur Mérieux Connaught ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE; INACTIVATED VIRUS VACCINE;

ANIMAL EXPERIMENT; ARTHRALGIA; ARTICLE; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; GOAT; GUINEA PIG; HEADACHE; HEPATITIS A VIRUS; HUMAN; IMMUNOGENICITY; MOUSE; MYALGIA; NONHUMAN; VIRUS ISOLATION;

ANIMALS; ANTIBODIES, VIRAL; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG EVALUATION, PRECLINICAL; FEMALE; HEPATITIS A VACCINES; HEPATOVIRUS; HUMANS; MALE; VIRAL HEPATITIS VACCINES;

EID: 0030449979     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01713047     Document Type: Article

References (154)

1. Feinstone, S. M., Kapikian, A. Z., Purcell, R. H.: Hepatitis A: detection by immune electron microscopy of a virus-like antigen associated with acute illness. Science 182 (1973) 1026-1029.
2. Frösner, G. G., Deinhart, F., Scheid, R., Gauss-Muller, V., Holmes, N., Messelberger, V., Siegl, G., Alexander, J. J.: Propagation of human hepatitis A virus in a hepatoma cell line. Infection 7 (1979) 303-306.
3. Provost, P. J., Hilleman, M. R.: Propagation of human hepatitis A virus in cell culture in vitro. Proc. Soc. Exp. Biol. Med. 160 (1979) 213-221.
4. Provost, P. J., Hilleman, M. R.: An inactivated hepatitis A virus vaccine prepared from infected marmoset liver. Proc. Soc. Exp. Biol. Med. 159 (1978) 201-203.
5. Binn, L. N., Bancroft, W. H., Lemon, S. M., Marchwicki, R. H., LeDuc, J. W., Trahan, C., Staley, E., Keenan, C.: Preparation of a prototype inactivated hepatitis A virus vaccine from infected cell cultures. J. Infect. Dis. 153 (1986) 749-756.
6. Gust, I. D.: Design of hepatitis A vaccines. Br. Med. Bull. 46 (1990) 319-328.
7. Siegl, G., Lemon, S. M.: Recent advances in hepatitis A vaccine development. Vir. Res. 17 (1990) 75-92.
8. Flehmig, B., Heinricy, U., Pfisterer, M.: Prospects for a hepatitis A virus vaccine. Prog. Med. Virol. 37 (1990) 56-71.
9. Lemon, S. M.: Hepatitis A virus: current concepts of the molecular virology, immunobiology, and approaches to vaccine development. Rev. Med. Virol. 2 (1992) 73-87.
10. Provost, P. J., Banker, F. S., Wadsworth, C. W., Krah, D. L.: Further evaluation of a live hepatitis A vaccine in marmosets. J. Med. Virol. 34 (1991) 227-231.
11. Karron, R. A., Daemer, R., Ticehurst, J. R., d'Hondt, E., Popper, H., Mihalik, K., Phillips, J., Feinstone, S. M., Purcell, R. H.: Studies of prototype live hepatitis A virus vaccines in primate model. J. Infect. Dis. 157 (1988) 338-345.
12. Flehmig, B., Mauler, R. F., Noll, G., Weinmann, E., Gregersen, J. P.: Progress in the development of an attenuated, live hepatitis A vaccine. In: Zuckerman, A. J. (ed.): Viral hepatitis and liver disease. Alan R. Liss, New York 1988, pp. 87-90.
13. Provost, P. J., Bishop, R. P., Gerety, R. J., Hilleman, M. R., McAleer, W. J., Scolnick, E. M., Stevens, C. E.: New findings in live, attenuated hepatitis A vaccine development. J. Med. Virol. 20 (1986) 165-175.
14. Mao, J. S., Chen, N. L., Huang, H. Y., Chai, S. A., Dong, D. X., Cao, Y. Y., Zhang, H. Y., Wu, D. M., Zhang, S. Y.: Development of live attenuated hepatitis A vaccine (H2-strain). Chin. Med. J. 105 (1992) 189-193.
15. Nalin, D. R., Kuter, B. J., Brown, L., Patterson, C., Calandra, G. B., Werzberger, A., Shouval, D., Ellerbeck, E. F., Block, S. L., Bishop, R. P., Wiens, B., Schwartz, S. W., Lewis, J. A., Sitrin, R. D., Provost, P. J., Miller, W. J., Ryan, J. L.: Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: an overview. J. Hepatol. 18 (1993) S51-S55.
16. Armstrong, M. E., Giesa, P. A., Davide, J. P., Redner, F., Waterbury, J. A., Rhoad, A. E., Keys, R. D., Provost, P. J., Lewis, J. A.: Development of the formalin-inactivated hepatitis A vaccine. VAQTA (TM) from the live attenuated virus strain CR326F. J. Hepatol. 18 (1993) S20-S26.
17. Flehmig, B., Haage, A., Heinricy, U., Pfisterer, M.: Studies with an inactivated hepatitis A vaccine. In: Zuckerman A. J. (ed.): Viral hepatitis and liver disease. Alan R. Liss, New York 1988, pp. 100-105.
18. André, F. E., d'Hondt, E., Delem, A. D., Safary, A.: Clinical assessment of the safety and efficacy of an inactivated hepatitis-A vaccine - rationale and summary of findings. Vaccine 10 (1992) S160-S168.
19. Clemens, R., Safary, A., Hepburn, A., Roche, C., Stanbury, W. J., Andre, F. E.: Clinical experience with an inactivated hepatitis A vaccine. J. Infect. Dis. 171 (Suppl. 1) (1995) S44-S49.
20. Pellegrini, V., Fineschi, N., Matteucci, G., Marsili, I., Nencioni, L., Puddu, M., Garelick, H., Zuckerman, A. J.: Preparation and immunogenicity of an inactivated hepatitis-A vaccine. Vaccine 11 (1993) 383-387.
21. Glück, R.: Immunopotentiating reconstituted influenza virosomes (-IRIVs) and other adjuvants for improved presentation of small antigens. Vaccine 10 (1992) 915-919.
22. Peetermans, J.: Production, quality control and characterization of an inactivated hepatitis-A vaccine. Vaccine 10 (1992) S99-S101.
23. Mengiardi, B., Berger, R., Just, M., Gluck, R.: Virosomes as carriers for combined vaccines. Vaccine 13 (1995) 1306-1315.
24. Innis, B. L., Snitbhan, R., Kunasol, P., Laorakpongse, T., Poopatanakool, W., Kozik, C. A., Suntayakorn, S., Suknuntapong, T., Safary, A., Tang, D. B., Boslego, J. W.: Protection against hepatitis A by an inactivated vaccine. J. Amer. Med. Assoc. 271 (1994) 1328-1334.
25. Werzberger, A., Mensch, B., Kuter, B., Brown, L., Lewis, J. A., Sitrin, R., Miller, W. J., Shouval, D., Wiens, B., Calandra, G. B., Ryan, J., Provost, P. J., Nalin, D. R.: A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N. Eng. J. Med. 327 (1992) 453-457.
26. Prikazsky, V., Olear, V., Cernoch, A., Safary, A., Andre, F. E.: Interruption of an outbreak of hepatitis A in two villages by vaccination. J. Med. Virol. 44 (1994) 457-459.
27. Frösner, G., Overby, L. R., Flehmig, B., Gerth, H. J., Haas, H., Decker, R. H., Ling, C. M., Zuckerman, A. J., Frosner, H. R.: Serological investigation of patients and family contacts in an epidemic of hepatitis A. J. Med. Virol. 1 (1977) 163-173.
28. Flehmig, B., Vallbracht, A., Wurster, G.: Hepatitis A in cell culture:3, Propagation of hepatitis virus in human embryo kidney cells and human embryo fibroblast strains. Med. Microbiol. Immunol. 170 (1981) 83-89.
29. Heinricy, U., Hentscel, J., Pfisterer, M., Flehmig, B.: Hepatitis A: biophysical characterization and electron microscopy of infectious hepatitis A virus. Zent. Bakteriol. Hyg. A257 (1983) 139-142.
30. Heinricy, U., Stierhof, Y. D., Pfisterer, M., Flehmig, B.: Properties of a hepatitis A virus candidate vaccine strain. J. Gen. Virol. 68 (1987) 2487-2493.
31. Graff, J., Normann, A., Feinstone, S. M., Flehmig, B.: Nucleotide sequence of wild-type hepatitis A virus GBM in comparison to two cell culture-adapted variants. J. Virol. 68 (1994) 548-554.
32. Graff, J., Kasang, C., Normann, A., Pfisterer Hunt, M., Feinstone, S. M., Flehmig, B.: Mutational events in consecutive passages of hepatitis A virus strain GBM during cell culture adaptation. Virology 204 (1994) 60-68.
33. Flehmig, B., Haage, A., Pfisterer, M.: Immunogenicity of a hepatitis A virus vaccine. J. Med. Virol. 22 (1987) 7-16.
34. Flehmig, B., Heinricy, U., Pfisterer, M.: Immunogenicity of a killed hepatitis A vaccine in seronegative volunteers. Lancet i (1989) 1039-1041.
35. Flehmig, B., Heinricy, U., Pfisterer, M.: Simultaneous vaccination for hepatitis A and B. J. Infect. Dis. 161 (1990) 865-868.
36. Miller, W. J., Clark, W., Hurni, W. M., Kuter, B., Schofield, T., Nalin, D. R.: Sensitive assays for hepatitis-A antibodies. J. Med. Virol. 41 (1993) 201-204.
37. Albrecht, P., van Steenis, G., van Wezel, A. L., Salk, J.: Standardization of poliovirus neutralizing antibody tests. Rev. Infect. Dis. 6 (1984) S540-S544.
38. Flehmig, B., Zahn, J., Vallbracht, A.: Levels of neutralizing and binding antibodies to hepatitis A virus after onset of icterus: a comparison. J. Infect. Dis. 150 (1984) 461.
39. Krah, D. L., Amin, R. D., Nalin, D. R., Provost, P. J.: A simple antigen-reduction assay for the measurement of neutralizing antibodies to hepatitis A virus. J. Infect. Dis. 163 (1991) 634-637.
40. Gerety, R. J., Smallwood, L. A., Finlayson, J. S., Tabor, E.: Standardization of the antibody to hepatitis A virus (anti-HAV) content of immunoglobulin. Dev. Biol. Stand. 54 (1983) 411-416.
41. Stapleton, J. T.: Passive immunization against hepatitis-A. Vaccine 10 (1992) S45-S47.
42. Kendall, B. J., Cooksley, W. G.: Prophylactic treatment regimens for the prevention of hepatitis A. Current concepts. Drugs 41 (1991) 883-888.
43. Lerman, Y., Shohat, T., Ashkenazi, S., Almog, R., Heering, S. L., Shemer, J.: Efficacy of different doses of immune serum globulin in the prevention of hepatitis A: a three-year prospective study. Clin. Infect. Dis. 17 (1993) 411-414.
44. Conrad, M. E., Lemon, S. M.: Prevention of endemic icteric viral hepatitis by administration of immune serum gamma globulin. J. Infect. Dis. 156 (1987) 56-63.
45. Krugman, S.: Effect of human immune serum globulin on infectivity of hepatitis A virus. J. Infect. Dis. 134 (1976) 70-74.
46. Winokur, P. L., Stapleton, J. T.: Immunoglobulin prophylaxis for hepatitis A. Clin. Infect. Dis. 14 (1992) 580-586.
47. Behrens, R. H., Doherty, J. F.: Severe hepatitis-A despite passive immunisation. Lancet 341 (1993) 972.
48. Safford, S., Needleman, S. B., Decker, R. H.: Radioimmunoassay for detection of antibody to hepatitis A virus: results of clinical evaluation. Am. J. Clin. Pathol. 74 (1980) 25-31.
49. Zaaijer, H. L., Leentvaarkuijpers, A., Rotman, H., Lelie, P. N.: Hepatitis. A antibody titres after infection and immunization - implications for passive and active immunization. J. Med. Virol. 40 (1993) 22-27.
50. Richtmann, R., Chaves, R. L., Mendonca, J. S., Konichi, S. R., Mitre, H. P., Takei, K., Dietz, K., Flehmig, B.: Immunogenicity and efficacy of a killed hepatitis A vaccine in day-care center children. J. Med. Virol. 48 (1995) 147-150.
51. Garin, D., Vidor, E., Wallon, M., Fanget, B., Brasseur, P., Delolme, H., Caron, F., Mojon, M., Gravey, A., Humbert, G., Flehmig, B., Peyron, F.: Good immunogenicity of GBM strain inactivated hepatitis A vaccine in healthy male adults. Vaccine 13 (1995) 220-224.
52. Goubau, P., Vangerven, V., Safary, A., Delem, A. D., Knops, J., d'Hondt, E., André, F. E., Desmyter, J.: Effect of virus strain and antigen dose on immunogenicity and reactogenicity of an inactivated hepatitis-A vaccine. Vaccine 10 (1992) S114-S118.
53. Goilav, C., Zuckerman, J. N., Lafrenz, M., Vidor, E., Lauwers, S., Ratheau, C., Benichou, G., Zuckerman, A. J.: Immunogenicity and safety of a new inactivated hepatitis A vaccine in a comparative study. J. Med. Virol. 46 (1995) 287-292.
54. Theilmann, L., Kallinowski, B., Gmelin, K., Hofmann, F., Scheiermann, N., Wohland, B., Stickl, H., Maiwald, H., Moriabadi, F. K., Bock, H. L., Clemens, R., Safary, A., André, F. E.: Reactogenicity and immunogenicity of 3 different lots of a hepatitis-A vaccine. Vaccine 10 (1992) S132-S134.
55. Fessard, C., Riche, O., Cohen, J. H. M.: Intramuscular versus subcutaneous injection for hepatitis B vaccine. Vaccine 6 (1988) 469-471.
56. Galy, M., Genet, A., Saliou, P.: Un progrès dans le domaine de l'injection sans aiguille: le système Imule S. T. P. Pharma Pratiques 4 (1992) 261-266.
57. Parent, I., Schlumberger, M., Lang, J., Soula, G., Genet, A.: Immunogenicity and tolerance of vaccines delivered by single-use IMULE system carpule. Vaccine (in press) (1996).
58. Hoke, C. H. Jr., Egan, J. E., Sjogren, M. H., Sanchez, J., Defraites, R. F., Macarthy, P. O., Binn, L. N., Rice, R, Burke, A., Hill, J.: Administration of hepatitis A vaccine to a military population by needle and jet injector and with hepatitis B vaccine. J. Infect. Dis. 171 (Suppl. 1) (1995) S53-S60.
59. Brindle, R., Morris, C. A., Berger, R., Kurtz, J. B.: Inadequate response to intradermal hepatitis A vaccine. Vaccine 12 (1994) 483-484.
60. Binn, L. N., Macarthy, P. O., Marchwicki, R. H., Sjogren, M. H., Hoke, C. H., Burge, J. R., d'Hondt, E.: Laboratory tests and reference reagents employed in studies of inactivated hepatitis-A vaccine. Vaccine 10 (1992) S102-S105.
61. Delem, A. D., Safary, A., Denamur, F., Hauser, P., d'Hondt, E.: Characterization of the immune response of volunteers vaccinated with a killed vaccine against hepatitis-A. Vaccine 11 (1993) 479-484.
62. Lemon, S. M.: Immunologic approaches to assessing the response to inactivated hepatitis A vaccine. J. Hepatol. 18 (1993) S15-S19.
63. Berger, R., Just, M., Althaus, B.: Time course of hepatitis A antibody production after active, passive and active/passive immunisation: the results are highly dependent on the antibody test system used. J. Virol. Meth. 43 (1993) 287-297.
64. Delem, A. D.: Comparison of modified HAVAB and ELISA for determination of vaccine-induced anti-HAV response. Biol. 20 (1992) 289-291.
65. Wiedermann, G., Ambrosch, F., Kollaritsch, H., Hofman, H., Kunz, C., d'Hondt, E., Delem, A. D., André, F. E., Safary, A., Stephenne, J.: Safety and immunogenicity of an inactivated hepatitis A candidate vaccine in healthy adult volunteers. Vaccine 8 (1990) 581-584.
66. Scheifele, D. W., Bjornson, G. J.: Evaluation of inactivated hepatitis-A vaccine in Canadians 40 years of age or more. Can. Med. Assoc. J. 148 (1993) 551-555.
67. Horng, Y. C., Chang, M. H., Lee, C. Y., Safary, A., André, F. E., Chen, D. S.: Safety and immunogenicity of hepatitis A vaccine in healthy adult volunteers. J. Gastroenterol. Hepatol. 8 (1993) 338-341.
68. Westblom, T. U., Gudipati, S., Derousse, C., Midkiff, B. R., Belshe, R. B.: Safety and immunogenicity of an inactivated hepatitis a vaccine: effect of dose and vaccination schedule. J. Infect. Dis. 169 (1994) 996-1001.
69. Ellerbeck, E. F., Lewis, J. A., Nalin, D. R., Gershman, K., Miller, W. J., Armstrong, M. E., Davide, J. P., Rhoad, A. E., McGuire, B., Calandra, G. B., Provost, P. J., Midthun, K.: Safety profile and immunogenicity of an inactivated vaccine derived from an attenuated strain of hepatitis A. Vaccine 10 (1992) 668-672.
70. Shouval, D., Ashur, Y., Adler, R., Lewis, J. A., Miller, W., Kuter, B., Brown, L., Nalin, D. R.: Safety, tolerability, and immunogenicity of an inactivated hepatitis A vaccine - effects of single and booster injections, and comparison to administration of immune globulin. J. Hepatol. 18 (1993) S32-S37.
71. Jilg, W., Bittner, R., Schatzt, H., Rasshofer, R., Schmidt, M., Deinhardt, F.: The immune response to different doses of inactivated hepatitis A vaccine. J. Hepatol. 18 (1993) S38-S40.
72. Loutan, L., Bovier, P., Althaus, B., Gluck, R.: Inactivated virosome hepatitis-A vaccine. Lancet 343 (1994) 322-324.
73. Just, M., Berger, H., Drechsler, H., Brantschen, S., Glück, R.: A single vaccination with an inactivated hepatitis A liposome vaccine induces protective antibodies after only two weeks. Vaccine 10 (1992) 737-739.
74. Glück, R., Mischler, R., Brantschen, S., Just, M., Althaus, B., Cryz, S. J.: Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. J. Clin. Invest. 90 (1992) 2491-2495.
75. Poovorawan, Y., Tieamboonlers, A., Chumdermpadetsuk, S., Glück, R., Cryz, S. J. Jr.: Control of a hepatitis A outbreak by active immunization of high-risk susceptible subjects (5). J. Infect. Dis. 169 (1994) 228-229.
76. Claesson, B. A., Iwarson, S. A.: Dose response study of an inactivated hepatitis A virus vaccine. J. Hepatol. 18 (1993) S41-S45.
77. Loutan, L., Bovier, P., Herzog, C., Gluck, R.: Inactivated virosome hepatitis A vaccine - reply. Lancet 343 (1994) 1166.
78. d'Hondt, E., Delem, A. D.: Inactivated virosome hepatitis A vaccine. Lancet 343 (1994) 1165-1166.
79. Tilzey, A. J., Palmer, S. J., Barrow, S., Perry, K. R., Tyrell, H., Safary, A., Banatvala, J. E.: Effect of hepatitis-A vaccination schedules on immune response. Vaccine 10 (1992) S121-S123.
80. Leentvaarkuijpers, A., Coutinho, R. A., Brulein, V., Safary, A.: Simultaneous passive and active immunization against hepatitis A. Vaccine 10 (1992) S138-S141.
81. Wagner, G., Lavanchy, D., Darioli, R., Pecoud, A., Brulein, V., Safary, A., Frei, P. C.: Simultaneous active and passive immunization against hepatitis A studied in a population of travellers. Vaccine 11 (1993) 1027-1032.
82. Green, M. S., Cohen, D., Lerman, Y., Sjogren, M. H., Binn, L. N., Zur, S., Slepon, R., Robin, G., Hoke, C. H., Bancroft, W. H., Safary, A., Danon, Y., Wiener, M.: Depression of the immune response to an inactivated hepatitis A vaccine administered concomitantly with immune globulin. J. Infect. Dis. 168 (1993) 740-743.
83. Wiedermann, G., Ambrosch, F., André, F. E., d'Hondt, E., Delem, A. D., Safary, A.: Persistence of vaccine-induced antibody to hepatitis A virus. Vaccine 10 (1992) S129-S131.
84. Berger, R., Just, M.: Vaccination against hepatitis A: control 3 years after the first vaccination. Vaccine 10 (1992) 295.
85. Totos, G., Papaevangelou, G.: Persistence of vaccine-induced antibodies for hepatitis A virus. Vaccine 12 (1994) 475.
86. Vandamme, P., Thoelen, S., Cramm, M., Groote de, K., Safary, A., Meheus, A.: Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence. J. Med. Virol. 44 (1994) 446-451.
87. Robertson, B. H., Jansen, R. W., Khanna, B. K., Totsuka, A., Nainan, O. V., Siegl, G., Widell, A., Margolis, H. S., Isomura, S., Ito, K., Ishizu, T., Moritsugu, Y., Lemon, S. M.: Genetic relatedness of hepatitis A virus strains recovered from different geographical regions. J. Gen. Virol. 73 (1992) 1365-1377.
88. Lemon, S. M., Jansen, R. W., Brown, E. A.: Genetic, antigenic and biological differences between strains of hepatitis A virus. Vaccine 10 (1992) S40-S44.
89. Lemon, S. M., Robertson, B. H.: Current perspectives in the virology and molecular biology of hepatitis A virus. Seminars in Virology 4 (1993) 285-295.
90. Green, M. S., Block, C.: Apparent effect of immune serum globulin prophylaxis in the military on viral hepatitis incidence in the civilian population in Israel. J. Epidemiol. Community Health 43 (1989) 187-190.
91. Green, M. S., Block, C., Slater, P. E.: Rise in the incidence of viral hepatitis in Israel despite improved socioeconomic conditions. Rev. Infect. Dis. 11 (1989) 464-469.
92. Anonymous: Hepatitis A vaccination (Havrix). Curr. Probl. Pharmacovigilance 20 (1994) 16.
93. Hughes, P. J., Saadeh, I. K., Cox, J. P. D. T., Illis, L. S.: Probable post-hepatitis A vaccination encephalopathy. Lancet 342 (1993) 302.
94. Steffen, R.: Risk of hepatitis A in travellers. Vaccine 10 (1992) S69-S72.
95. Steffen, R., Kane, M. A., Shapiro, C. N., Billo, N., Schoellhorn, K. J., Vandamme, P.: Epidemiology and prevention of hepatitis A in travelers. J. Amer. Med. Assoc. 272 (1994) 885-889.
96. Rubertone, M. V., Defraites, R. F., Krauss, M. R., Brandt, C. A.: An outbreak of hepatitis A during a military field training exercise. Milit. Med. 158 (1993) 37-41.
97. Jefferson, T. O., Behrens, R. H., Demicheli, V.: Should British soldiers be vaccinated against hepatitis A? An economic analysis. Vaccine 12 (1994) 1379-1383.
98. Brewer, M. A., Edwards, K. M., Decker, M. D.: Who should receive hepatitis A vaccine? Pediatr. Infect. Dis. J. 14 (1995) 258-260.
99. Margolis, H. S., Shapiro, C. N.: Who should receive hepatitis A vaccine - considerations for the development of an immunization strategy. Vaccine 10 (1992) S85-S87.
100. Rosenblum, L. S., Villarino, M. E., Nainan, O. V., Melish, M. E., Hadler, S. C., Pinsky, P. P., Jarvis, W. R., Ott, C. E., Margolis, H. S.: Hepatitis A outbreak in a neonatal intensive care unit: risk factors for transmission and evidence of prolonged viral excretion among preterm infants. J. Infect. Dis. 164 (1991) 476-482.
101. Thacker, S. B., Addiss, D. G., Goodman, R. A., Holloway, B. R., Spencer, H. C.: Infectious diseases and injuries in child day care: opportunities for healthier children. J. Amer. Med. Assoc. 268 (1992) 1720-1726.
102. Desenclos, J. C. A., Maclafferty, L.: Community wide outbreak of hepatitis A linked to children in day care centres and with increased transmission in young adult men in Florida 1988-9. J. Epidemiol. Community Health 47 (1993) 269-273.
103. Bell, J. C., Crewe, E. B., Capon, A. G.: Seroprevalence of hepatitis A antibodies among residents of a centre for people with developmental disabilities. Aust. N. Z. J. Med. 24 (1994) 365-367.
104. Hofmann, F., Wehrle, G., Berthold, J., Koster, D.: Hepatitis A as an occupational hazard. Vaccine 10 (1992) S82-S84.
105. Germanaud, J., Barthez, J. P., Causse, X.: Prévalence des anticorps anti-virus de l'hépatite A chez le personnel d'un centre hospitalier. Gastroenterol. Clin. Biol. 16 (1992) 816-817.
106. Germanaud, J.: Hepatitis A and health care personnel. Arch. Intern. Med. 154 (1994) 820-822.
107. Van Damme, P., Cramm, M., Vanderauwera, J. C., Meheus, A.: Hepatitis A vaccination for health care workers. Br. Med. J. 306 (1993) 1615.
108. Hadler, S. C., McFarland, L.: Hepatitis A in day care centers: epidemiology and prevention. Rev. Infect. Dis. 8 (1994) 548-557.
109. Jacques, P., Moens, G., Vandamme, P., Goubau, P., Vranckx, R., Steeno, J., Muylle, L., Desmyter, J.: Increased risk of hepatitis A among female day-nursery workers in Belgium. Vaccine 12 (1994) 958.
110. Doebbeling, B. N., Li, N., Wenzel, R. P.: An outbreak of hepatitis A among health care workers - risk factors for transmission. Amer. J. Pub. Health 83 (1993) 1679-1684.
111. Lee, K. K., Vargo, L. R., Lê, C. H., Fernando, L.: Transfusion-acquired hepatitis A outbreak from fresh frozen plasma in a neonatal intensive care unit. Pediatr. Infect. Dis. J. 11 (1992) 122-123.
112. Skinhoj, P., Hollinger, F. B.: Infectious liver diseases in three groups of Copenhagen workers: correlation of hepatitis A infection to sewage exposure. Arch. Environ. Health 36 (1981) 139-143.
113. Poole, C. J. M., Shakespeare, A. T.: Should sewage workers and carers for people with learning disabilities be vaccinated for hepatitis A. Br. Med. J. 306 (1993) 1102.
114. Vonstille W. T., Stille, W. T., Sharer, R. C.: Hepatitis A epidemics from utility sewage in Ocoee, Florida. Arch. Environ. Health 48 (1993) 120-124.
115. Schlosser, O., Roudot-Thoraval, F.: Exposition professionnelle aux eaux usées et risque d'hépatite virale A. Bull. Epidémiol. Hebd. 12 (1994) 54-55.
116. Cadilhac, P., Roudot-Thoraval, F.: Evaluation du risque de contamination par le virus de l'hépatite A du personnel travaillant en égouts. Enquète transversale. Bull. Epidémiol. Hebd. 31 (1994) 139-141.
117. Heng, B. H., Goh, K. T., Doraisingham, S., Quek, G. H.: Prevalence of hepatitis A virus infection among sewage workers in Singapore. Epidemiol. Infect. 113 (1994) 121-128.
118. Maguire, H., Poole, C. J. M., Calvert, I. A.: Hepatitis A virus infection: risk to sewage workers unproved (8). Br. Med. J. 307 (1993) 561.
119. Poole, C. J. M., Calvert, I. A.: Hepatitis A virus infection - reply. Br. Med. J. 307 (1993) 561.
120. Anand, J. K.: Hepatitis A vaccine for sewage workers. Br. Med. J. 305 (1992) 477.
121. Koster, D., Hofmann, F., Berthold, H.: Hepatitis A immunity in food-handling occupations. Eur. J. Clin. Microbiol. Infect. Dis. 9 (1990) 304-305.
122. Anonymous: Prevention of foodborne hepatitis A. Weekly Epidemiol. Rec. 68 (1993) 25-26.
123. Lowry, P. W., Levine, R., Stroup, D. F., Gunn, R. A., Wilder, M. H., Konigsberg, C. J.: Hepatitis A outbreak on a floating restaurant in Florida, 1986. Amer. J. Epidemiol. 129 (1989) 155-164.
124. Niu, M. T., Polish, L. B., Robertson, B. H., Khanna, B. K., Woodruff, B. A., Shapiro, C. N., Miller, M. A., Smith, J. D., Gedrose, J. K., Alter, M. J., Margolis, H. S.: Multistate outbreak of hepatitis A associated with frozen strawberries. J. Infect. Dis. 166 (1992) 518-524.
125. Warburton, A. R., Wreghitt, T. G., Rampling, A., Buttery, R., Ward, K. N., Perry, K. R., Parry, J. V.: Hepatitis A outbreak involving bread. Epidemiol. Infect. 106 (1991) 199-202.
126. Kani, J., Nandwani, R., Gilson, R. J., Johnson, A. M., Maguire, H. C., Tedder, R. S.: Hepatitis A virus infection among homosexual men. Br. Med. J. 302 (1991) 1399.
127. Leentvaarkuijpers, A., Kool, J. L., Veugelers, P. J., Coutinho, R. A., Vangriensven, G. J. P.: An outbreak of hepatitis A among homosexual men in Amsterdam. 1991-1993. Int. J. Epidemiol. 24 (1995) 218-222.
128. Atkins, M., Zambon, M., Watkins, P.: Hepatitis A virus infection - should susceptible homosexual men be offered immunisation. Br. Med. J. 307 (1993) 562.
129. Nandwani, R., Caswell, S., Boag, F., Lawrence, A. G., Coleman, J. C.: Hepatitis A seroprevalence in homosexual and heterosexual men. Genit. Med. 70 (1994) 325-328.
130. Mannucci, P. M.: Outbreak of hepatitis A among Italian patients with haemophilia. Lancet 339 (1992) 819.
131. Gerritzen, A., Schneweis, K. E., Brackman, H. H., Oldenburg, J., Hanfland, P., Lesesve, J. F., Caspari, G.: Acute hepatitis A in haemophiliacs. Lancet 340 (1992) 1231-1232.
132. Peerlinck, K., Vermylen, J.: Acute hepatitis-A in patients with haemophilia-A. Lancet 341 (1993) 179.
133. Temperley, I. J., Cotter, K. P., Walsh, T. J., Power, J., Hillary, I. B.: Clotting factors and hepatitis A. Lancet 340 (1992) 1466.
134. Vermylen, J., Peerlinck, K.: Review of the hepatitis A epidemics in hemophiliacs in Europe. Vox Sang. 67 (1994) 8-11.
135. Purcell, R. H., Mannucci, P. M., Gdovin, S., Gringeri, A., Colombo, M., Mele, A., Shinaia, N., Ciavarella, N., Emerson, S. U.: Virology of the hepatitis A epidemic in Italy. Vox Sang. 67 (1994) 2-7.
136. Normann, A., Graff, A., Gerritzen, A., Brackman, H. H., Flehmig, B.: Detection of hepatitis A virus RNA in commercially available factor VIII preparation. Lancet 340 (1992) 1232-1233.
137. Mannucci, P. M., Gdovin, S., Gringeri, A., Colombo, M., Mele, A., Schinaia, N., Ciavarella, N., Emerson, S. U., Purcell, R. H.: Transmission of hepatitis-A to patients with hemophilia by factor-VIII concentrates treated with organic solvent and detergent to inactivate viruses. Ann. Intern. Med. 120 (1994) 1-7.
138. Prowse, C.: Hepatitis A virus infection: no conclusive link to factor VIII (9). Br. Med. J. 307 (1993) 561-562.
139. Robinson, S. M., Schwinn, H., Smith, A.: Clotting factors and hepatitis A. Lancet 340 (1992) 1465.
140. Richards, E. M., Wreghitt, T. G., Baglin, T. P.: Prevalence of serum IgG antibodies to hepatitis A virus in Cambridge haemophiliacs. Transf. Med. 4 (1994) 91-92.
141. Turner, P. C., Eglin, R. E., Woodward, C. G., Dave, J.: Screening before hepatitis A vaccination. Lancet 340 (1992) 1160.
142. Germanaud, J., Causse, X.: Strategy of vaccination against hepatitis A. Presse Médicale 22 (1993) 1014.
143. Behrens, R. H., Roberts, J. A.: Is travel prophylaxis worthwhile? Economic appraisal of prophylactic measures against malaria, hepatitis A, and typhoid in travellers. Br. Med. J. 309 (1994) 918-922.
144. Gray, G. C., Rodier, G. R.: Prevaccination screening for citizens of the United States living abroad who are at risk for hepatitis A. Clin. Infect. Dis. 19 (1994) 225-226.
145. Damme Van, P., Tormans, G., Doorslaer, E. V.: Hepatitis A vaccination. Lancet 340 (1992) 617.
146. Bryan, J. P., Nelson, M.: Testing for antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines. Arch. Intern. Med. 154 (1994) 663-668.
147. Zuckerman, J. N., Powell, L.: Hepatitis A antibodies in attenders of London travel clinics: cost-benefit of screening prior to hepatitis A immunisation. J. Med. Virol. 44 (1994) 393-394.
148. Vandoorslaer, E., Tormans, G., Vandamme, P.: Cost-effectiveness analysis of vaccination against hepatitis A in travellers. J. Med. Virol. 44 (1994) 463-469.
149. Stuart, J. M., Majeed, F. A., Cartwright, K. A. V., Room, R., Parry, J. V., Perry, K. R., Begg, N. T.: Salivary antibody testing in a school outbreak of hepatitis A. Epidemiol. Infect. 109 (1992) 161-166.
150. Hurni, W. M., Laufer, D., Miller, W. J., Ryan, J., Watson, B.: Anti-hepatitis A in the general population and in hepatitis A vaccines using saliva and serum as diagnostic media. Ann. New York Acad. Sci. 694 (1993) 289-292.
151. Laufer, D. S., Hurni, W., Watson, B., Miller, W., Ryan, J., Nalin, D., Brown, L.: Saliva and serum as diagnostic media for antibody to hepatitis A virus in adults and in individuals who have received an inactivated hepatitis A vaccine. Clin. Infect. Dis. 20 (1995) 868-871.
152. Santagostino, E., Gringeri, A., Rocino, A., Zanetti, A., De Biasi, R., Mannucci, P. M.: Patterns of immunogenicity of an inactivated hepatitis A vaccine in anti-HIV positive and negative hemophilic patients. Thromb. Haemost. 72 (1994) 508-510.
153. Hess, G., Clemens, R., Bienzle, U., Schonfeld, C., Schunck, B., Bock, H. L.: Immunogenicity and safety of an inactivated hepatitis A vaccine in anti-HIV positive and negative homosexual men. J. Med. Virol. 46 (1995) 40-42.
154. Lemon, S. M., Shapiro, C. N.: The value of immunization against hepatitis A. Infect. Agents Dis. 3 (1994) 38-49.